Koumaki Dimitra, Koumaki Vasiliki, Lagoudaki Eleni, Bertsias George
Dermatology Department, University Hospital of Heraklion, Crete, Greece.
Microbiology Department, Medical School of Athens, Athens, Greece.
Eur J Case Rep Intern Med. 2019 Dec 19;7(1):001383. doi: 10.12890/2019_001383. eCollection 2020.
Baricitinib is an orally active Janus kinase (JAK) inhibitor used in the treatment of moderate to severe rheumatoid arthritis (RA).
Here, we report the case of a 56-year-old Caucasian male diagnosed with RA who developed palmoplantar pustulosis (PPP) while being treated with baricitinib.
The patient's PPP resolved after discontinuation of baricitinib and recurred when this was restarted. Based on causality assessment, it was considered a drug-induced PPP.
To the authors' knowledge, this is the first case of baricitinib-induced PPP.
Baricitinib is a small, orally active molecule that inhibits JAK-1 and JAK-2, which is used in the treatment of rheumatoid arthritis.Baricitinib has been also used in the treatment of psoriasis, alopecia areata and atopic dermatitis.Palmoplantar pustulosis is a rare cutaneous side effect of baricitinib.
巴瑞替尼是一种口服活性的 Janus 激酶（JAK）抑制剂，用于治疗中度至重度类风湿性关节炎（RA）。
在此，我们报告一例 56 岁的白种男性病例，该患者被诊断为 RA，在接受巴瑞替尼治疗时出现了掌跖脓疱病（PPP）。
停用巴瑞替尼后患者的 PPP 消退，重新开始使用时复发。根据因果关系评估，认为这是药物性 PPP。
据作者所知，这是首例巴瑞替尼诱发的 PPP 病例。
巴瑞替尼是一种抑制 JAK-1 和 JAK-2 的小分子口服活性分子，用于治疗类风湿性关节炎。巴瑞替尼也已用于治疗银屑病、斑秃和特应性皮炎。掌跖脓疱病是巴瑞替尼罕见的皮肤副作用。
